phrykt

Cartesian Therapeutics, Inc. (RNAC): who owns it and who trades it

As of Nov 16, 2026, RNAC insiders reported 3 open-market sales worth $259K and 1 purchase worth $206K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Carsten Brunn (CEO), with $162K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cartesian Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RNAC

94 funds and institutions reported RNAC shares worth $90.7M at the end of Q2 2026, about 30% of the company. The largest holder is Squarepoint Ops LLC with 7.7%.

Funds and institutions (13F) 30%Everyone else 70%

10 largest owners, by share of the company

Squarepoint Ops LLC7.7%
BlackRock, Inc.2.8%
683 Capital Management, LLC2.2%
Vanguard Capital Management LLC1.9%
FMR LLC (Fidelity)1.3%
Geode Capital Management, LLC1.2%
AQR Capital Management LLC1.2%
Millennium Management LLC1.1%
Two Sigma Investments, LP1.0%
State Street Corp0.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Squarepoint Ops LLC2.25M7.67%$23.5M+1%
BlackRock, Inc.819,2392.79%$8.5M+37%
683 Capital Management, LLC650,0002.21%$6.8M+97%
Vanguard Capital Management LLC555,8231.89%$5.8M+36%
FMR LLC (Fidelity)368,4291.25%$3.8M-54%
Geode Capital Management, LLC356,5251.21%$3.7M+35%
AQR Capital Management LLC356,4561.21%$3.7M+324%
Millennium Management LLC309,8871.05%$3.2M+9%
Two Sigma Investments, LP296,2931.01%$3.1M+77%
State Street Corp249,2120.85%$2.6M+24%
Marshall Wace, LLP232,9190.79%$2.4M-7%
UBS Group AG208,6470.71%$2.2M+52%
Jupiter Topco LLC200,9050.68%$2.1MNew
Privium Fund Management B.V.151,6750.52%$1.6M-15%
Northern Trust Corp105,6980.36%$1.1M+15%
ADAR1 Capital Management, LLC98,8770.34%$1MNew
Vanguard Fiduciary Trust Co91,8540.31%$957K+31%
Vanguard Portfolio Management LLC87,3170.30%$910K+44%
Diadema Partners LP87,0570.30%$907KNew
Bank of America Corp84,6240.29%$882KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RNAC insiders reported $206K of open-market purchases and $259K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$206K
1 trades, 1 people
Sales, 12 months
$259K
3 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jan 6, 2026
Filed Jan 8, 2026

Purchases and sales by month

$259K$259KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jan 6, 2026Carsten BrunnCEOSale23,766$6.82$162KForm 4
Jan 6, 2026Milos MiljkovicChief Medical OfficerSale3,573$6.82$24.4KForm 4
Jan 6, 2026Blaine DavisCFOSale10,591$6.82$72.2KForm 4
Dec 4, 2025Timothy C BarabeDirectorPurchase30,000$6.86$206KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Timothy C BarabeDirector$206K–Dec 4, 2025
Carsten BrunnPresident and CEO, Director–$162KJan 6, 2026
Blaine DavisChief Financial Officer–$72.2KJan 6, 2026
Milos MiljkovicChief Medical Officer–$24.4KJan 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RNAC short interest

Moderate short interest. 6.3% of RNAC shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.92M RNAC shares were sold short, 6.3% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 116,169 shares, buying them all back would take about 16.5 trading days (days to cover).

Shares short, % of all shares

6.33%May 15Oct 308.08%

Days to cover

16.5May 15Oct 3020.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.92M6.33%+2%116,16916.5
Oct 15, 20261.88M6.20%+1%159,82311.7
Sep 30, 20261.86M6.13%+3%146,84312.6
Sep 15, 20261.80M5.96%-0%106,10517.0
Aug 31, 20261.81M5.99%-3%135,43913.4
Aug 14, 20261.87M6.17%+1%104,62517.9
Jul 31, 20261.84M6.09%-4%123,81314.9
Jul 15, 20261.93M6.55%+2%156,52412.3
Jun 30, 20261.89M6.42%-2%384,6124.9
Jun 15, 20261.93M6.56%-16%594,3733.2
May 29, 20262.29M7.80%+3%185,31512.4
May 15, 20262.22M7.54%+2%186,61911.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cartesian Therapeutics company events

Cartesian Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 29, 2026AnnouncementThe Company announced additional retreatment data from the Company’s Phase 2 trial of Descartes-08 in patients with MG. The data consisted of observations from five participants who experienced recurrence of MG symptoms (as measured by Myasthenia Gravis Activities of Daily Living ≥6) following… Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 17, 2026VoteReported shareholder vote results. Filing
  5. Jun 9, 2026AnnouncementShared information with investors. Filing
  6. May 26, 2026LeadershipMilos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company. Filing
  7. Apr 30, 2026ResultsReleased financial results. Filing
  8. Mar 30, 2026LeadershipMurat Kalayoglu, M.D., Ph.D., a member of the Board of Directors of Cartesian Therapeutics, Inc., notified the Company of his intent to resign from the Board, effective as of March 31, 2026, to pursue other opportunities. Filing
  9. Mar 9, 2026ResultsReleased financial results. Filing
  10. Jan 9, 2026AnnouncementShared information with investors. Filing
  11. Dec 18, 2025LeadershipThe Board of Directors of Cartesian Therapeutics, Inc. appointed Adrian Bot, M.D., Ph.D. as a Class II director. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cartesian Therapeutics financials

Famous investors that hold RNAC

4 of the 50 well-known investors we track reported holding RNAC in their latest 13F filing. The largest position is Israel Englander's, worth $1.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026221,858$1.6M0.0%-28%
Jim Simons · Renaissance TechnologiesQ3 202672,200$521K0.0%+256%
Ken Griffin · Citadel AdvisorsQ3 202670,005$505K0.0%New
Steve Cohen · Point72 Asset ManagementQ3 202647,783$345K0.0%+10%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RNAC in the last 120 days.

FiledHolderFormStake
Nov 6, 2026Barclays PLC13G/A0.0%
Nov 6, 2026Barclays PLC13G/A0.0%

Questions about Cartesian Therapeutics, Inc. (RNAC) stock

Who owns the most RNAC stock?

The largest reported owner of Cartesian Therapeutics, Inc. (RNAC) is Squarepoint Ops LLC, with 7.7% of the company. In total, 94 funds and institutions reported holding RNAC at the end of Q2 2026, together about 30% of the shares. See the largest owners.

Are RNAC insiders buying or selling?

In the last 12 months, RNAC insiders reported 1 open-market purchase worth $206K and 3 sales worth $259K. The latest trade was on Jan 6, 2026. See every trade.

What is the short interest in RNAC?

As of Oct 30, 2026, 1.92M RNAC shares were sold short, 6.3% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 116,169 shares, buying them all back would take about 16.5 trading days (days to cover). See the history.

Which famous investors hold RNAC?

4 of the 50 well-known investors we track reported RNAC in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $1.6M. See all holders.

Executive pay

Cartesian Therapeutics's chief executive was paid a total of $4.3M for the year ended Dec 31, 2025, down 41% from $7.3M the year before. In the last 12 months, Cartesian Therapeutics's executives and directors bought $206K of stock on the open market and sold $259K.

Chief executive, total pay$4.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.